The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England
Open accessAbstract
BACKGROUND: In September 2015, the United Kingdom introduced the multicomponent meningococcal group B vaccine (4CMenB, Bexsero) into its publicly funded national immunization program at a reduced two-dose priming schedule for infants, with a 12-month booster. METHODS: Using data from enhanced national surveillance of invasive meningococcal disease in England, we evaluated the effect of vaccination on the incidence of meningococcal group B disease during the first 3 years of the program. The effect of vaccination was assessed by comparing the observed incidence of disease with the expected incidence based on the incidence during the 4-year prevaccination period in equivalent cohorts and with the use of disease trends in cohorts of children younger than 5 years of age who were not eligible to receive the vaccine. Vaccine effectiveness was estimated with the use of the indirect screening method. RESULTS: 4CMenB uptake in England remained consistently high; data from the first 3 months of 2018 showed that 92.5% of children had completed the primary immunizations by their first birthday and 87.9% had received all three doses by 2 years. From September 2015 through August 2018, the incidence of meningococcal group B disease in England (average annual birth cohort, approximately 650,000 infants) was significantly lower in vaccine-eligible cohorts than the expected incidence (63 observed cases as compared with 253 expected cases; incidence rate ratio, 0.25; 95% confidence interval [CI], 0.19 to 0.36), with a 75% reduction in age groups that were fully eligible for vaccination. The adjusted vaccine effectiveness against meningococcal group B disease was 52.7% (95% CI, -33.5 to 83.2) with a two-dose priming schedule for infants and 59.1% (95% CI, -31.1 to 87.2) with a two-dose priming schedule plus a booster at 1 year). Over the 3-year period, there were 169 cases of meningococcal group B disease in the vaccine-eligible cohorts, and an estimated 277 cases (95% CI, 236 to 323) were prevented. CONCLUSIONS: The 4CMenB program was associated with continued positive effect against meningococcal group B disease in children in England, and protection after three doses of the vaccine was sustained for at least 2 years. (Funded by Public Health England.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parikh, S. R., Andrews, N. J., Beebeejaun, K., Campbell, H., Ribeiro, S., Ward, C., White, J. M., Borrow, R., Ramsay, M. E., & Ladhani, S. N. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31921-3 · Cited by 275
Self-citationThe epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014
Whittaker, R., Dias, J. G., Ramliden, M., Ködmön, C., Economopoulou, A., Beer, N., Pastore Celentano, L., Kanitz, E., Richter, L., Mattheus, W., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.007 · Cited by 179
Self-citation
Research works printed but not linked: 25
- 10.1080/21645515.2018.1451810 · DOI
- 10.1056/NEJMra0906357 · DOI · Paper page
- 10.1073/pnas.1013758107 · DOI · Paper page
- 10.1016/S1473-3099(13)70006-9 · DOI · Paper page
- 10.1186/s12879-015-1247-7 · DOI
- 10.1016/j.jinf.2013.06.007 · DOI
- 10.1093/ije/22.4.742 · DOI · Paper page
- 10.1503/cmaj.130257 · DOI
- 10.1136/archdischild-2015-308928 · DOI
- 10.1016/j.vaccine.2010.11.064 · DOI
- 10.1016/j.vaccine.2017.05.023 · DOI
- 10.1016/S1473-3099(18)30048-3 · DOI
- 10.1093/cid/cix154 · DOI
- 10.1542/peds.2014-4015 · DOI
- 10.1056/NEJMoa1514866 · DOI
- 10.1080/07448481.2017.1312418 · DOI
- 10.15585/mmwr.mm6520a3 · DOI
- 10.2807/1560-7917.ES.2018.23.28.1700590 · doi:10.2807/1560-7917.es.2018.23.28.1700590
- 10.1086/656741 · DOI · Paper page
- 10.1056/NEJMoa1514866 · DOI
- 10.1016/S2352-4642(18)30103-2 · DOI
- 10.1016/j.vaccine.2018.10.095 · DOI
- 10.2807/1560-7917.ES.2018.23.17.17-00468 · DOI
- 10.1136/archdischild-2017-314152 · DOI
- 10.1056/NEJMoa1900236 · DOI · Paper page
Cited by
Mbaeyi, S. A., Bozio, C. H., Duffy, J., Rubin, L. G., Hariri, S., Stephens, D. S., & MacNeil, J. R. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6909a1 · Cited by 321
Community-acquired bacterial meningitis.
van de Beek, D., Brouwer, M. C., Koedel, U., & Wall, E. C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00883-7 · Cited by 292
Parikh, S. R., Campbell, H., Bettinger, J. A., Harrison, L. H., Marshall, H. S., Martinon-Torres, F., Safadi, M. A., Shao, Z., Zhu, B., von Gottberg, A., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.05.079 · Cited by 274
Self-citation
Metadata
- Authors
- Ladhani, S. N., Andrews, N., Parikh, S. R., Campbell, H., White, J., Edelstein, M., Bai, X., Lucidarme, J., Borrow, R., & Ramsay, M. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-01-23
- Volume
- 382
- Issue
- 4
- Pages
- 309-317
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3001806777
- Cited by
- 210
- References
- 2
- FWCI
- 21.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- Public Health England (N/A)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.